See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing targeted therapies for solid tumors
aurabiosciences.comLast updated
In short: Aura Biosciences completed enrollment for its Phase 3 CoMpass trial of bel-sar and secured $299 million through a public stock offering.
Jeremy Bender, Ph.D., M.B.A., is a biotechnology leader with experience in late-stage development and commercialization. He joins as the company advances bel-sar toward potential approval.
Topline data expected in second half of 2027. Bel-sar may become first approved vision-preserving therapy for early choroidal melanoma.
Phase 3 CoMpass trial nearing enrollment completion; topline data expected in 2H 2027. New CEO appointed, and $299M equity financing strengthened cash position.
The offering includes full exercise of underwriters' option, selling 46 million shares and pre-funded warrants at $6.00 per share.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to...
Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.
Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and...
Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing...
Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Aura Biosciences and other trending companies.